Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
PRTKDelisted Stock | USD 2.18 0.00 0.00% |
About 56% of Paratek Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Paratek Pharmaceuticals suggests that many traders are alarmed regarding Paratek Pharmaceuticals' prospects. Paratek Pharmaceuticals' investing sentiment shows overall attitude of investors towards Paratek Pharmaceuticals.
Paratek |
BOSTON, May 01, 2023 -- Paratek Pharmaceuticals, Inc. today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 430 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under Events and Presentations in the Investor Relations section of the Companys website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial 800-920-3371 and internation
Read at finance.yahoo.com
Paratek Pharmaceuticals Fundamental Analysis
We analyze Paratek Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paratek Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paratek Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Paratek Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Paratek Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Paratek Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Paratek Pharmaceuticals Related Equities
LYRA | Lyra Therapeutics | 5.00 | ||||
LPTX | Leap Therapeutics | 4.43 | ||||
ADAP | Adaptimmune Therapeutics | 3.23 | ||||
CRVS | Corvus Pharmaceuticals | 1.12 | ||||
JSPR | Jasper Therapeutics | 0.40 | ||||
IMMP | Immutep | 2.75 | ||||
AFMD | Affimed NV | 2.93 | ||||
EQ | Equillium | 4.11 | ||||
APTO | Aptose Biosciences | 5.26 | ||||
HOOK | Hookipa Pharma | 7.88 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |